Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study
References (20)
- et al.
Cytokines in symptomatic asthmatic airways
J Allergy Clin Immunol
(1992) - et al.
Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis
Lancet
(1989) - et al.
Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma
J Allergy Clin Immunol
(1992) - et al.
Effects of cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects
Lancet
(1991) - et al.
Mucosal inflammation in asthma
Am Rev Respir Dis
(1990) - et al.
Expression of mRNA for interleukins in mucosal bronchial biopsies from asthma
J Clin Invest
(1991) - et al.
Generation and metabolism of 5-lipoxygenase pathway leukotrienes by human eosinophils: Predominant production of leukotriene C4
Proc Natl Acad Sci USA
(1983) - et al.
Leukotrienes, LTC4 and LTB4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases
J Allergy Clin Immunol
(1988) - et al.
Role of inflammatory mediators in asthma
Br Med Bull
(1992) - et al.
Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4 and histamine in asthmatics
Am Rev Respir Dis
(1992)
Cited by (155)
Leukotriene D<inf>4</inf> role in allergic asthma pathogenesis from cellular and therapeutic perspectives
2020, Life SciencesCitation Excerpt :Zafirlukast antagonizes LTD4- and exercise-induced bronchoconstriction [129]. Results from placebo-controlled trial showed that zafirlukast produced early and sustained effects in the treatment of mild-to-moderate asthma [130]. A clinical study showed that LTD4 inhalation causes bronchoconstriction in asthmatics on maintenance inhaled corticosteroid therapy and a single dose of zafirlukast inhibited this mediated effect [131].
Evaluating the role of leukotriene-modifying drugs in asthma management: Are their benefits ‘losing in translation’?
2016, Pulmonary Pharmacology and TherapeuticsDevelopment of smart cell-free and cell-based assay systems for investigation of leukotriene C<inf>4</inf> synthase activity and evaluation of inhibitors
2016, Biochimica et Biophysica Acta - Molecular and Cell Biology of LipidsCitation Excerpt :After release from the cell, LTC4 is processed in the extracellular space by sequential cleavage of glutamic acid and glycine residues to LTD4 and LTE4, respectively [14,15]. Cys-LTs evoke their effects via G protein-coupled receptors (CysLT1 and CysLT2) [16,17] and CysLT1 is sensitive to antagonists (e.g. montelukast or zafirlukast) used for treatment of asthma [18,19]. However, selective antagonists to CysLT2 are still lacking, and distinct studies suggest a role in other pro-inflammatory events since LTC4S deletion in mice revealed increasing endothelial permeability and exacerbating inflammatory gene expression [20,21].
Leukotriene Modifiers
2008, Clinical AsthmaPeroxisome proliferator-activated receptor α-independent effects of peroxisome proliferators on cysteinyl leukotriene production in mast cells
2007, European Journal of PharmacologyTraditional Chinese Herbal Medicine for Allergic Diseases: A Review
2023, American Journal of Chinese Medicine
- 1
Members of the Zafirlukast Trialists Group are listed in the Acknowledgments.